UCB Targets Covidien Unit Over Ritalin Patent

Law360, New York (April 16, 2012, 12:38 PM EDT) -- Belgian pharmaceutical giant UCB Inc. on Thursday hit Covidien PLC subsidiary Mallinckrodt Inc. with a patent infringement suit over the rival drugmaker's plan to sell a generic version of Ritalin, UCB's attention deficit and hyperactivity disorder treatment.

UCB says Mallinckrodt filed an abbreviated new drug application with the U.S. Food and Drug Administration so that it could sell a generic version of Mallinckrodt's Metadate CD, a time-released version of methylphenidate.

The complaint, filed in Delaware federal court, claims UCB's patent on Metadate won't expire until 2020...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.